Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study
Authors:
- Hee Seo SonHSHee Seo Son
- Cheol Young OhCOCheol Young Oh
- Myung-Soo ChooMCMyung-Soo Choo
- Hyeong Gon KimHKHyeong Gon Kim
- Joon Chul KimJKJoon Chul Kim
- Kyu-Sung LeeKLKyu-Sung Lee
- Dong Gil ShinDSDong Gil Shin
- Sung Yong ChoSCSung Yong Cho
- Seong Jin JeongSJSeong Jin Jeong
- Ju Tae SeoJSJu Tae Seo
- Hana YoonHYHana Yoon
- Hong Sang MoonHMHong Sang Moon
Open Access
- 30 June 2022
- journal article
- research article
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 26 (2) , 119-128
Abstract
Purpose: DA-8010 is a novel muscarinic M3 receptor antagonist with significant selectivity for bladder over salivary gland in preclinical studies. We evaluated the clinical efficacy and safety of DA-8010 in overactive bladder (OAB) patients.Methods: This phase 2, randomized, double-blind, parallel-group, active reference- and placebo-controlled trial was conducted at 12 centers in South Korea (NCT03566134). Patients aged ≥19 years with OAB symptoms for ≥3 months were enrolled. Three hundred six patients (30.07% male) were randomized to 12 weeks of treatment among 4 groups; 2 experimental groups (DA-8010 2.5 or 5 mg), an active reference group (solifenacin 5 mg), and a placebo group. The change from the baseline of (=∆) 24-hour frequency at 12 weeks (primary endpoint), episodes of urgency, overall/urgency urinary incontinence, average/ maximum voided volume, nocturia, and patients’ subjective responses were analyzed.Results: In the full analysis set, the mean (standard deviation) [median] values for ∆ 24-hour frequency at 12 weeks were -1.01 (2.44) [-1.33] for placebo, -1.22 (2.05) [-1.33] for DA-8010 2.5 mg, and -1.67 (2.25) [-1.67] for DA-8010 5 mg; DA-8010 5 mg showed a significant decrease compared with placebo (P=0.0413). At 4 and 8 weeks, both DA-8010 2.5 mg (P=0.0391 at 4 weeks, P=0.0335 at 8 weeks) and DA-8010 5 mg (P=0.0001 at 4 weeks, P=0.0210 at 8 weeks) showed significant decrease in ∆ 24-hour frequency compared with placebo. DA-8010 5 mg achieved a significant decrease in ∆ number of urgency episodes, compared with placebo at 4 (P=0.0278) and 8 (P=0.0092) weeks. Adverse drug reactions (ADRs) were observed in 3.95% of placebo, 6.67% of DA-8010 2.5 mg, 18.42% of DA-8010 5 mg, and 17.33% of solifenacin 5 mg groups. No serious ADRs were observed in any patient.Conclusions: Both DA-8010 2.5 mg and 5 mg showed therapeutic efficacy for OAB without serious ADRs. Therefore, both dosages of DA-8010 can advance to a subsequent large-scale phase 3 trial.Keywords
Funding Information
- Dong-A ST Co., Ltd. (DA-8010)
This publication has 15 references indexed in Scilit:
- Detection of muscarinic receptor subtypes in human urinary bladder mucosa: Age and gender‐dependent modificationsNeurourology and Urodynamics, 2007
- Muscarinic receptor antagonists for overactive bladderBJU International, 2007
- Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderBritish Journal of Pharmacology, 2006
- The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-AnalysisEuropean Urology, 2005
- A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M 3 selective receptor antagonist, in the treatment of overactive bladderBJU International, 2005
- Darifenacin, an M3 Selective Receptor Antagonist, is an Effective and Well-Tolerated Once-Daily Treatment for Overactive BladderEuropean Urology, 2004
- Antimuscarinics for treatment of overactive bladderThe Lancet Neurology, 2004
- Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding studyBJU International, 2003
- Muscarinic receptor subtypes and management of the overactive bladderUrology, 2002
- Which muscarinic receptor is important in the bladder?World Journal of Urology, 2001